Amneal Pharmaceuticals (AMRX) AI Stock Analysis

• Market Cap: $4.17B
• Dividend Yield: N/A
• Average Volume (3M): 1.67M
• Price to Earnings (P/E): 928.9
• Beta (1Y): 0.85
• Revenue Growth: 9.50%
• EPS Growth: N/A
• Country: US
• Employees: 8,300
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): 0.17
• Shares Outstanding: 314,362,900
• 10 Day Avg. Volume: 1,405,000
• 30 Day Avg. Volume: 1,665,470
• PEG Ratio: 1.00
• Price to Book (P/B): -22.40
• Price to Sales (P/S): 0.88
• P/FCF Ratio: 10.06
• Enterprise Value/Market Cap: 1.24
• Enterprise Value/Revenue: 1.76
• Enterprise Value/Gross Profit: 4.80
• Enterprise Value/Ebitda: 9.31
• 1Y Price Target: $13.75
• Price Target Upside: 4.25% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 4
• EPS Forecast (FY): 0.94
• Revenue Forecast (FY): $3.21B

• Rating: 58 Neutral
• Price Target: $14.00 ▲(6.14% Upside)

Amneal Pharmaceuticals' stock score is primarily influenced by its strong technical indicators, suggesting positive momentum. However, the high P/E ratio raises concerns about overvaluation. Financial performance shows steady growth but challenges in profitability and cash flow growth. The earnings call and corporate events highlight strong operational performance and strategic initiatives, but these factors are not weighted in the final score.

Positive Factors

Revenue Growth

Consistent revenue growth reflects the company's expanding market presence and successful product launches, indicating strong business fundamentals.

FDA Approvals

FDA approvals enhance Amneal's product portfolio, supporting long-term growth and competitive positioning in critical therapeutic areas.

Debt Refinancing

Refinancing reduces financial risk and interest expenses, improving cash flow and financial flexibility for future investments.

Negative Factors

Gross Margin Decline

Declining gross margins may pressure profitability, indicating challenges in cost management and competitive pricing in the market.

Free Cash Flow Growth

Negative free cash flow growth limits the company's ability to reinvest in business expansion and manage financial obligations effectively.

Biosimilars Competition

Intense competition in the biosimilars market could impact market share and profitability, requiring strategic focus and innovation.

Amneal Pharmaceuticals Business Overview & Revenue Model

Company Description

Amneal Pharmaceuticals, Inc., together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic and specialty pharmaceutical products for various dosage forms and therapeutic areas. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment develops, manufactures, and commercializes complex oral solids, injectables, ophthalmics, liquids, topicals, softgels, inhalation products, and transdermals across a range of therapeutic categories. The Specialty segment is involved in the development, promotion, distribution, and sale of branded pharmaceutical products with focus on central nervous system disorders, endocrinology, parasitic infections, and other therapeutic areas. It also offers Emverm, a chewable tablet for the treatment of pinworm, whipworm, common roundworm, common hookworm, and American hookworm in single or mixed infections; Rytary to treat Parkinson's disease; and Unithroid for the treatment of hypothyroidism. The AvKARE segment provides pharmaceuticals, medical and surgical products, and services primarily to governmental agencies, the Department of Defense, and the Department of Veterans Affairs. It is also involved in the wholesale distribution of bottle and unit dose pharmaceuticals under the AvKARE and AvPAK names, as well as medical and surgical products; and packaging and wholesale distribution of pharmaceuticals and vitamins to its retail and institutional customers. The company sells its products through wholesalers, distributors, hospitals, chain pharmacies, and individual pharmacies. It operates in the United States, India, Ireland, and internationally. The company was formerly known as Atlas Holdings, Inc. and changed its name to Amneal Pharmaceuticals, Inc. in 2018. Amneal Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Bridgewater, New Jersey.

How the Company Makes Money

Amneal Pharmaceuticals generates revenue primarily through the sale of generic and specialty pharmaceutical products. Its key revenue streams include the commercialization of generic drugs, which are sold at competitive prices to pharmacies, wholesalers, and healthcare providers. The company also earns revenue from specialty products that often entail higher margins compared to generic offerings, particularly in therapeutic areas that require more complex formulations. Additionally, Amneal benefits from strategic partnerships and collaborations with other pharmaceutical companies, which can enhance its product offerings and expand market reach. The company’s commitment to research and development allows it to continuously innovate and bring new products to market, contributing to long-term revenue growth.

Amneal Pharmaceuticals Financial Statement Overview

Summary

Amneal Pharmaceuticals shows steady revenue growth and efficient cost management, reflected in a healthy gross profit margin. However, challenges remain with low net profit margins and moderate operational efficiency. The balance sheet indicates improved leverage but limited profitability from equity. Strong cash flow generation is offset by negative free cash flow growth.

Income Statement

Amneal Pharmaceuticals shows a modest revenue growth rate of 2.88% in the TTM, indicating steady sales performance. The gross profit margin is healthy at 36.76%, reflecting efficient production and cost management. However, the net profit margin is low at 0.20%, suggesting challenges in translating revenue into profit. The EBIT and EBITDA margins are moderate at 10.74% and 18.93%, respectively, indicating reasonable operational efficiency but room for improvement in profitability.

Balance Sheet

The company's debt-to-equity ratio has improved significantly to 0.15 in the TTM, demonstrating a reduction in leverage and improved financial stability. However, the return on equity is low at 5.06%, indicating limited profitability from shareholders' investments. The equity ratio stands at 22.78%, suggesting a moderate level of financial stability but potential vulnerability to financial fluctuations.

Cash Flow

Operating cash flow is strong with a coverage ratio of 0.38, indicating good cash generation relative to net income. However, free cash flow growth is negative at -6.73%, highlighting challenges in maintaining cash flow growth. The free cash flow to net income ratio is 0.75, suggesting that a significant portion of earnings is converted to free cash flow, but there is room for improvement.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	2.93B	2.79B	2.39B	2.21B	2.09B	1.99B
Gross Profit	1.08B	1.02B	863.87M	791.46M	768.97M	628.39M
EBITDA	555.65M	439.77M	500.78M	440.21M	401.10M	345.61M
Net Income	5.90M	-116.89M	-83.99M	-129.99M	10.62M	91.06M
Balance Sheet
Total Assets	3.60B	3.50B	3.47B	3.80B	3.94B	4.01B
Cash, Cash Equivalents and Short-Term Investments	201.25M	112.42M	93.74M	27.80M	247.79M	343.07M
Total Debt	2.69B	2.59B	2.75B	2.85B	2.88B	3.00B
Total Liabilities	3.71B	3.55B	3.41B	3.59B	3.57B	3.65B
Stockholders Equity	-109.46M	-109.27M	19.78M	298.42M	360.34M	303.27M
Cash Flow
Free Cash Flow	244.82M	220.11M	276.39M	-25.50M	194.09M	317.16M
Operating Cash Flow	327.75M	295.10M	345.58M	65.10M	241.82M	379.00M
Investing Cash Flow	-82.87M	-63.00M	-69.19M	-174.31M	-194.18M	-317.55M
Financing Cash Flow	-82.61M	-211.79M	-212.57M	-106.62M	-138.12M	131.81M

Amneal Pharmaceuticals Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 13.19
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AMRX, the sentiment is Positive. The current price of 13.19 is above the 20-day moving average (MA) of 12.88, above the 50-day MA of 12.31, and above the 200-day MA of 9.52, indicating a bullish trend. The MACD of 0.27 indicates Positive momentum. The RSI at 63.05 is Neutral, neither overbought nor oversold. The STOCH value of 69.84 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for AMRX.

Amneal Pharmaceuticals Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
AMPH	79 Outperform	$1.28B	11.53	14.84%	―	-0.03%	-27.66%
ANIP	66 Neutral	$1.91B	52.31	7.83%	―	48.87%	―
AMRX	58 Neutral	$4.17B	928.87	―	―	9.50%	―
SUPN	55 Neutral	$2.97B	-147.48	-1.86%	―	4.54%	-130.59%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
PRGO	49 Neutral	$2.05B	-40.27	-0.65%	8.48%	-2.55%	66.00%
ALVO	42 Neutral	$1.49B	21.49	―	―	55.38%	―

Amneal Pharmaceuticals Corporate Events

Amneal Pharmaceuticals Files Routine Regulation FD Disclosure Report

On January 13, 2026, Amneal Pharmaceuticals, Inc. filed a report under the Securities Exchange Act of 1934, formally executed on behalf of the company by Executive Vice President and Chief Financial Officer Anastasios Konidaris, who also serves as the principal financial and accounting officer. The filing, which incorporates financial disclosure from another section by reference, represents a routine but important procedural step in the company’s ongoing financial reporting and regulatory compliance obligations, underscoring the CFO’s central role in certifying Amneal’s public disclosures for investors and regulators.

The most recent analyst rating on (AMRX) stock is a Buy with a $15.00 price target. To see the full list of analyst forecasts on Amneal Pharmaceuticals stock, see the AMRX Stock Forecast page.

Amneal Pharmaceuticals Reports Strong Q3 2025 Results

Amneal Pharmaceuticals reported its financial results for the third quarter of 2025, with net revenue reaching $785 million, a 12% increase from the previous year, and a net income of $2 million. The company’s growth was driven by key branded products like CREXONT® and new launches such as BREKIYA® in the migraine space, alongside a strong performance in their Affordable Medicines segment. Amneal updated its 2025 full-year guidance, reflecting increased expectations for adjusted EBITDA and diluted EPS, highlighting the company’s strategic positioning and momentum as it enters 2026.

The most recent analyst rating on (AMRX) stock is a Buy with a $11.00 price target. To see the full list of analyst forecasts on Amneal Pharmaceuticals stock, see the AMRX Stock Forecast page.